Before SELECT, obesity was a risk factor. After SELECT, it became a treatable cardiovascular condition. That distinction may seem semantic, but it represents the most significant paradigm shift in cardiology since the statin trials of the 1990s. And the implications are still reverberating through every level of medicine, from clinical practice guidelines to insurance coverage decisions to how physicians fundamentally think about adipose tissue.
What SELECT Actually Showed
The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) enrolled 17,604 adults with established cardiovascular disease and a BMI of 27 or greater, but without diabetes. This last criterion was critical: it meant SELECT was testing whether treating obesity itself—independent of diabetes—could reduce cardiovascular events.
The answer was unambiguous. Semaglutide 2.4 mg weekly reduced the composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 20%. This hazard ratio of 0.80 was not just statistically significant—it was practice-changing.
Why This Changed Everything
For decades, the medical establishment maintained an uncomfortable ambivalence about obesity treatment. While acknowledging excess weight as a health risk, many physicians viewed obesity medications with skepticism—a skepticism reinforced by the catastrophic failures of earlier weight loss drugs from fenfluramine to rimonabant. The prevailing attitude was that obesity was a lifestyle problem requiring lifestyle solutions, and pharmaceutical intervention was at best a crutch and at worst dangerous.
SELECT demolished this framework. Here was a randomized, double-blind, placebo-controlled trial—the gold standard of medical evidence—showing that a GLP-1 medication didn't just help people lose weight. It prevented heart attacks and strokes. It saved lives.
The 20% MACE reduction places semaglutide in the same therapeutic league as statins for secondary cardiovascular prevention. For context, the landmark 4S trial showed simvastatin reduced major coronary events by 34%, and that trial transformed cardiology. SELECT is doing the same for obesity medicine.
The Downstream Effects
The practical consequences of SELECT have been enormous. Insurance coverage decisions that previously denied GLP-1 medications as "cosmetic" or "lifestyle" drugs are being reversed. The Medicare coverage provision for obesity medications, set to take effect in January 2027, was directly influenced by SELECT's cardiovascular evidence. Clinical practice guidelines from the American Heart Association and American College of Cardiology now explicitly reference SELECT in their recommendations for obesity management in patients with cardiovascular disease.
Perhaps most importantly, SELECT changed the conversation in the exam room. Physicians who previously hesitated to prescribe obesity medications now have Level 1 evidence supporting intervention. The question has shifted from "should we treat obesity pharmacologically?" to "can we afford not to?"
What Comes Next
SELECT answered the cardiovascular question for semaglutide. But the field is not standing still. SURMOUNT-MMO is evaluating tirzepatide's cardiovascular outcomes. The FLOW trial has already demonstrated semaglutide's renal protective effects. Trials are underway examining GLP-1 effects on heart failure outcomes (STEP-HFpEF), liver disease (ESSENCE), and even neurological conditions.
Each positive result further solidifies the paradigm that SELECT established: GLP-1 medications are not just weight loss drugs. They are cardiometabolic medicines with effects that extend far beyond the number on a scale. SELECT did not just change how physicians think about obesity. It changed how we think about what these medications are and what they can do.
We are living in the post-SELECT era. And there is no going back.